PROGRAMS

Registration opens at 7:00am each day

 

 

7:00am  Continental Breakfast (Ballroom Foyer)

 

8:00am  Welcome by the Conference Chair

                Dr. Joseph Bolen, CSO, Millennium: The Takeda Oncology Company

 

8:15am  Welcome by the Hon. Michael A. Nutter, Mayor of Philadelphia

 

8:30am  Keynote Address 

               The Ubiquitin-Proteasome Pathway and Drug Development:

                Dr. Alfred L. Goldberg Professor of Cell Biology
                Harvard Medical School, Boston MA

 

Session 1 Understanding the Ubiquitome
Session Chair:  Dr. Joseph Bolen, Millennium: The Takeda Oncology Company

 

9:15am  Assembly and Structure of the Eukaryotic Proteasome

               Dr. Mark Hochstrasser
               Yale University

 

9:40am  Proteomic and informatic approaches in the study of the Ubiquitin Pathway

                Dr. Wade Harper
                Harvard Medical School
  
10:05am Coffee Break
 
10:40am Modulation of prion formation by the ubiquitin proteasome system

                 and actin cytoskeleton
                 Dr. Keith D. Wilkinson, Emory University

 

11:05am Postsynaptic mechanisms of ubiquitination and de-ubiquitination involved in

                 Dr. Gentry Patrick
                 University of California, San Diego

 

11:30am Chemically ubiquitylated PCNA as a probe for eukaryotic translesion synthesis

                 Dr. Zhihao Zhuang
                 University of Delaware

 

11:45am Modulating activity of a deubiquitinating enzyme OTUB1 via phosphorylatio
                 Dr. Mariola Edelmann
                 Mississippi State University

 

12:00pm Lunch in the Swann Restaurant

 

Session 2 Targeting Deubiquitylases for Therapy

 

1:30pm  Enzyme regulatory mechanisms of USP7
                Dr. James Ernst
                Genentech, Inc.

1:55pm  Ubiquitin Specific Proteases as novel drug targets – A case study

                Dr. Jonathan D. Wrigley
                AstraZeneca
  
2:20pm  Discovery of Ubiquitin Isopeptidase Inhibitors             
                Dr. Ben Nicholson
                Progenra, Inc.

 

2:45pm The EXCRT-DUBs USP8 and AMSH Modulate ESCRT-0 to Control Receptor

                Transit through the Sorting Endosome
                 Dr. Piers Nash 
                 University of Chicago

 

3:00pm  Coffee Break

 

3:20pm  Deubiquitylases and exploration of chemical space

                Dr. Christopher P. Austin
                NIH Chemical Genomics Center

 

3:40pm  Quantitative assays for classification of ubiquitin-proteasome drugs reveal a

                Dr. Tsui-Fen Chou

                Howard Hughes Medical Institute, California Institute of Technology

 

3:55pm  Specificity of DUB inhibitors in cells profiled by

                Dr. Benedikt M. Kessler
                Oxford University

 

4:20pm  Inhibition of proteasomal deubiquitinating enzyme Usp14

               Dr. Dan Finley
               Harvard University

 

4:45pm  Dubya, an IAP-directed deubiquitylase controls Drosophila cell death

                Dr. Michael J. Thomenius
                Duke University Medical Center

 

5:00pm  Business Roundtable Discussion Groups
  
(1) Biotech and Pharma Partnership: The new face of the industry

 

Many forces are at work to change the pharma industry. Lack of drug approvals to address for unmet needs, health care reform, and mergers of major pharmaceutical companies have created a new business climate. The drug discovery model is changing rapidly as pharma tries to reduce its cost and yet keep core R and D functions. What role will small biotech play in filling the pipeline of pharma development? Does the ubiquitome provide an opportunity for the discovery of novel drugs?

(2) Academia and Industry Partnership: Translational Research

 

Unprecedented developments in “omics” driven science has created exciting opportunities for drug discovery in academia. NIH Road Map initiatives solicit “translational medicine” grant applications that are having a direct impact on drug discovery and diagnostics. At the same time, during economic stress and the resulting lack of jobs in the private sector, more academic researchers are competing for limited amounts of federal funds. There has never been the greater need to establish academic and industry partnerships to bring new technologies to the market. Academic colleagues are encouraged to offer their views on ways academic labs can develop joint programs with biotechs.

(3) Role of the NIH in Drug Discovery

 

Historically the NIH has played a key role in development of drugs, many of which are currently in use. Recent bold actions taken by the NIH have created new programs that have the potential to change the face of drug discovery. Natural products have been the source of many marketed drugs, and the NIH has made its extensive collection of natural products extracts available to countless drug discovery (screening) campaigns. In addition, the National Center for Chemical Genomics at NIH is spearheading programs to identify small molecule probes that will act as key tools for validating drug targets and as important drug leads. Although these NIH programs are not well publicized, scientists in academia and industry are encouraged to benefit from the opportunities that they provide.

 

6:00pm  Poster Viewing & Cocktail Hour
 
7:30pm  Dinner in the Ballroom Rounds

 

Wednesday, August 25, 2010  
 
7:00am  Continental Breakfast in the Ballroom Foyer

Session 3 Targeting E3 ligases for therapy

 

8:30am  Novel Mechanism-based E1 Inhibitors in Drug Discovery

               Dr. Jesse Chen
               Millennium: The Takeda Oncology Company
 
8:55am Structural Insights and Functional Complexity of E2 - RING Finger E3 Interactions

               Dr. Allan Weissman
               National Cancer Institute at Frederick (MD)

 

9:20am  Regualation of the cell cycle by the SCFCyclin F ubiquitin ligase complex

               Dr. Michele Pagano
               Howard Hughes Medical Institute, New York University School of Medicine

 

9:45am Mechanism for recognition of polyubiquitin chains: Balancing affinity through

               Dr. Leo Spyracopoulos
               University of Alberta

 

10:00am Coffee Break

 

10:40am Identification of E3 Ligase Inhibitors Using a Novel Assay

                Dr. Michael Eddins
                Progenra, Inc.  

 

11:05am Modulation of Parkin E3 Ligase Activity with Small Molecules
                 Dr. Jennifer Johnston
                 Elan Pharmaceuticals, Inc.  

 

11:30am HectH9 inhibitors as potential anti-cancer therapeutics
                 Dr. Stefanie Peter
                 University of Würzburg

 

11:45am KF-1 ubiquitin ligase: anxiety suppressor model

                Dr. Tamotsu Hashimoto-Gotoh
                Kyoto Prefectural University of Medicine

 

12:00pm Lunch in Swann Restaurant

Session 4 Ubiquitin Pathway Inhibitors in the Clinic  

 

1:30pm ONX0912:  an in vitro and in vivo evaluation of an orally bioavailable proteasome

               Dr. Shirin Kapur
               Onyx Pharmaceuticals

 

1:55pm  Proteomics of mitotic ubiquitome of Xenopus laevis embryo
                Dr. Jacek Kubiak
                University of Montreal

 

2:05pm  A Proteomics Approach to Profile Human Ubiquitome

               Dr. Yi Shi
               Baylor College of Medicine

 

2:20pm  Targeting Protein Degradatation as a Therapeutic Strategy in Myeloma   
                Dr. Kenneth Anderson
                Dana-Farber Cancer Institute
 
2:45pm Preventing the UPS-dependent degradation of frataxin, the protein defective in

               Friedreich’s Ataxia
               Dr. Silvia Fortuni
               University of Rome
  
3:00pm  Coffee Break

 

3:30pm   Role of proteasome inhibition in organ transplantation
                 Dr. E. Steve Woodle
                 University of Cincinnati

 

3:55pm Inhibition of NEDD8-activating enzyme for cancer treatment: Preclinical

               Dr. Peter G. Smith
               Millennium: The Takeda Oncology Company

 

4:20pm  Effective Proteasome Inhibitors for Inflammation and Septic Shock

                Dr. Nilofer Qureshi
                University of Missouri, Kansas City

 

4:35pm  Autophagy inhibition for myeloma therapy
                Dr. Dan Vogl
                University of Pennsylvania

 

5:00pm   Conference Concludes
 

 View the Pre-Conference Workshop Program